Abstract Library

#4659 Current role of systemic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) sporadic and hereditary

Introduction: Retrospective, performed in prospective manner single-arm, open-label, case series study to assess the efficacy of lanreotide in patients with unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations.

Conference:

Presenting Author:

Authors: Kolasińska-Ćwikla A, Pęczkowska M, Michałowska I, Pałucki J, Roszkowska-Purska K,

Keywords: Paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations, Lanreotide therapy, fractionated metoxycatecholamines,

#4615 Dosimetry, efficacy and safety of radiolabelled somatostatin receptor antagonist in patients with metastatic pheochromocytoma or paraganglioma

Introduction: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with a heterogenous phenotype and a variable treatment response. The SSTR antagonist [177Lu]Lu177Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses than standard radioligand therapy (RLT) with [177Lu]Lu-DOTA-TOC (177Lu-TOC).

Conference:

Presenting Author: Lider S

Authors: Lider Burciulescu S, Schmidt F, McDougall L, Bernhardt P, Mushaweh A,

Keywords: Metastatic PPGL, radioligand therapy, somatostatin receptor antagonist, dosimetry,

#4589 Clinical efficacy of RLT to assess OS and PFS using 177Lu DOTATATE, 90Y DOTATATE, and a mixture of both in patients with advanced, unresectable, progressive rectal NET – A retrospective analysis

Introduction: Retrospective, single-arm, open-label, case series study evaluating the efficacy of different types of radioligand therapy (RLT): 177Lu, 90Y DOTATATE, or mix of both used in advanced, unresectable progressive rectal NETG1/G2.

Conference:

Presenting Author: Ćwikła J

Authors: Kolasińska-Ćwikla A, Sankowski A, Pałucki J, Sekelcka N, Ćwikła J,

Keywords: Rectal Neuroendocrine Tumour, SST Receptor, Radioligand Therapy (RLT),

#4497 Complex management of a long-term gastrinoma survivor with multimodal treatment approaches

Introduction: The prognosis of pancreatic gastrinomas is influenced by tumour burden, extent of metastasis, and treatment response, with 5-year survival rates ranging from 20% to 40%. Treatment for well-differentiated tumours typically include locoregional therapies, long-acting somatostatin analogues, molecular targeted agents, radionuclides, and chemotherapy.

Conference:

Presenting Author: Puscasu A

Authors: Puscasu A, Miron M, Croitoru A,

Keywords: gastrinoma, neuroendocrine tumour, long survival, complex management,

#4410 NETest can predict the tumour burden in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are rare malignancies characterised by slow growth and a lack of reliable biomarkers for predicting tumour burden, treatment response, and prognosis.

Conference:

Presenting Author:

Authors: You T, Zhou N, Tang H, Ying J, Wang C,

Keywords: NETest, biomarker, NET,